Press release content from PR Newswire. The AP news staff was not involved in its creation.
Everlywell Signs Agreement to Distribute FDA-Authorized Rapid Antigen Testing for Organizations and Public Health Agencies
January 8, 2021 GMT
Founded in 2015, Everlywell was created to modernize the lab testing experience. Today the company offers a suite of validated lab tests that anyone can take at home. www.everlywell.com (PRNewsfoto/EverlyWell)
Founded in 2015, Everlywell was created to modernize the lab testing experience. Today the company offers a suite of validated lab tests that anyone can take at home. www.everlywell.com (PRNewsfoto/EverlyWell)
AUSTIN, Texas, Jan. 8, 2021 /PRNewswire/ Everlywell, a leading digital health company and provider of one of the only FDA-authorized at-home sample collection kits for COVID-19, today announced it has signed an agreement with leading life sciences company Ginkgo Bioworks to distribute Access Bio’s FDA-authorized CareStart™ COVID-1
Lateral Flow Assays Market Is Projected To Reach USD 10 2 Billion By 2025 From USD 8 2 Billion In 2020, At A CAGR Of 4 5%
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Intrivo Diagnostics Secures National Distribution Agreement with McKesson Medical-Surgical for Access Bio CareStart™ COVID-19 Tests
LOS ANGELES, Dec. 17, 2020
NDC, Inc. as key national partners within the Healthcare Supply Chain to help bring the CareStart™ line of COVID-19 testing products to the US market.
“Our agreement with McKesson Medical-Surgical is a monumental step in our efforts to reopen America through the use of rapid testing on a mass scale. By enhancing our supply chain to ensure greater access to Access Bio’s testing products, we can play a large role in curbing the spread of this virus,” said Reeve Benaron, Founder, Chairman and CEO, Intrivo Diagnostics. “We are delighted to welcome McKesson to our family of authorized distributors.”
Ginkgo Bioworks Funds Expansion of Rapid Antigen Test Manufacturing with Access Bio in New Jersey
November 22, 2020
Securing access to 10 million rapid antigen tests, which are EUA authorized and available today through Concentric by Ginkgo
BOSTON, Nov. 20, 2020 /PRNewswire/ Today, Ginkgo Bioworks announced it has secured access to at least 10 million rapid antigen test kits from Access Bio, a global in vitro diagnostics company. The tests will be available through Concentric by Ginkgo, the company’s end-to-end service for COVID-19 testing, for organizations seeking to use testing as part of their broader public health strategies. Additionally, Ginkgo provided capital to expand manufacturing capacity at Access Bio’s New Jersey factory for production of rapid diagnostic tests.
NDC, Inc. as key national partners within the Healthcare Supply Chain to help bring the CareStart™ line of COVID-19 testing products to the US market.
“Our agreement with McKesson Medical-Surgical is a monumental step in our efforts to reopen America through the use of rapid testing on a mass scale. By enhancing our supply chain to ensure greater access to Access Bio’s testing products, we can play a large role in curbing the spread of this virus,” said Reeve Benaron, Founder, Chairman and CEO, Intrivo Diagnostics. “We are delighted to welcome McKesson to our family of authorized distributors.”
As Access Bio’s exclusive US commercialization partner, Intrivo’s new channel agreements will expand the supply chain for the
vimarsana © 2020. All Rights Reserved.